ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kampelmacher, M.
Right arrow Articles by Lammers, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kampelmacher, M.
Right arrow Articles by Lammers, J.
Eur Respir J 1997; 10: 828-833
Copyright © ERS Journals Ltd 1997


Clinical Trial

Transtracheal oxygen therapy: an effective and safe alternative to nasal oxygen administration

MJ Kampelmacher, M Deenstra, RG van Kesteren, CF Melissant, JM Douze, and JW Lammers

Transtracheal oxygen therapy (TTOT) improves the efficiency of oxygen delivery and overcomes the discomfort associated with nasal oxygen delivery in patients on long-term oxygen therapy (LTOT). In addition, TTOT improves compliance and quality of life, and may reduce morbidity. Experience with TTOT in Europe is, however, scarce and the safety of TTOT has not yet been completely determined. These were reasons for testing the acceptance, efficacy and safety of TTOT. Patients were selected on the basis of the accepted indications and contraindications for TTOT. In 75 patients (48 males and 27 females) the mean follow-up time was 16 (range 0.5-51.5) months. Compared to nasal cannulae, TTOT caused a reduction in the oxygen flow rate of 47 (33-60)% at rest and a significant increase in the number of hours that oxygen was used. All patients on TTOT used oxygen for at least 20 h x day(-1). Most patients saw the procedure as a minor intervention. It was usually performed on an out-patient basis. In 34 patients, 51 mainly minor complications were seen, and most of these occurred in the first 10 patients. After precautions had been taken, complications occurred less frequently. No patient needed to be hospitalized because of a complication. TTOT had to be stopped in two patients; nevertheless, all patients preferred TTOT to the nasal cannulae. We conclude that transtracheal oxygen therapy is an effective and safe alternative to nasal oxygen administration, provided that it is restricted to a well-defined group of patients and applied by a motivated and experienced group of physicians.


This article has been cited by other articles:


Home page
JAMAHome page
S. D. Halpern and J. Hansen-Flaschen
Terminal withdrawal of life-sustaining supplemental oxygen.
JAMA, September 20, 2006; 296(11): 1397 - 1400.
[Full Text] [PDF]


Home page
ChestHome page
A. Ernst, G. A. Silvestri, and D. Johnstone
Interventional Pulmonary Procedures: Guidelines from the American College of Chest Physicians
Chest, May 1, 2003; 123(5): 1693 - 1717.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. SCHNEIDER, D. J. O'HEARN, K. LEBLANC, P. L. SMITH, C. P. O'DONNELL, D. W. EISELE, J. H. PETER, and A. R. SCHWARTZ
High-flow Transtracheal Insufflation Treats Obstructive Sleep Apnea . A Pilot Study
Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1869 - 1876.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.